Literature DB >> 15792675

Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation.

Masahiro Yasaka1, Toshiyuki Sakata, Hiroaki Naritomi, Kazuo Minematsu.   

Abstract

We investigated optimal dose of prothrombin complex concentrate (PCC) for acute reversal of oral anticoagulation in patients with major hemorrhagic complications or who required invasive procedures. We also checked how rapidly international normalized ratio (INR) was reversed after PCC administration. INR was measured before and 10-60 min after administration of PCC with or without vitamin K in 42 patients (men 28, women 14, median age of 70 years old) who had received warfarin but required rapid reversal of INR because of a hemorrhagic complication or medical procedure. The amount of PCC administered was 200 IU in six patients, 500 IU in 30, 1000 IU in 3, and 1500 IU in the other 3. Additional administration of PCC was performed when the correction of INR was inadequate. In 10 of the 42 cases, INR was measured serially, before, 10 and 60 min and 12-24 h after the administration of PCC and vitamin K. In the six patients who received PCC of 200 IU, INR values of 3.34 median (range 2.06 to 5.08) decreased to 1.85 (range 1.23 to 2.43) significantly (Wilcoxon's rank sum test, p=0.028), but in three patients (50%), INR values were still above 2.0 after the administration. In 30 patients treated with PCC of 500 IU, values decreased from 2.49 median (range 1.54 to 10.00) to 1.19 (range 0.87 to 1.55) significantly (p<0.0001). The corrected INR values were below 1.5 in 25 of 26 patients (96%) who had initial INR values from 2.0 to 4.9. In four patients with initial INR of 5.0 or more, the reversed INR was below 1.5 in one (25%), between 1.5 and 2.0 in two (50%), and above 2.0 in one (25%) who had additional administration of 500 IU PCC lowering INR from 2.01 to 1.48. Values of INR in the six patients receiving 1000 IU or 1500 IU, INR decreased from 2.33 median (range 1.96 to 4.00) to 0.96 (range 0.87 to 1.24, p=0.028). In the 10 patients with serial measurement, INR changed from 2.67 median (range 2.05 to 10.00) to 1.17 (range 0.99 to 1.60) 10 min after the administration. The INR values remained stable 60 min and 12-24 h after the PCC administration. The 500 IU of PCC is likely to be optimal dose of PCC for emergent reversal of INR in patients requiring rapid correction of INR below 5.0, but to be inadequate dose in patients with INR of 5.0 or more. PCC administration with vitamin K may finish reversing INR rapidly within 10 min and keep the reversed INR values for 12-24 h.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15792675     DOI: 10.1016/j.thromres.2004.09.002

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  22 in total

Review 1.  [Fresh plasma and concentrates of clotting factors for therapy of perioperative coagulopathy: what is known?].

Authors:  B Heindl; M Spannagl
Journal:  Anaesthesist       Date:  2006-09       Impact factor: 1.041

2.  Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0.

Authors:  Wesley R Zemrak; Kathryn E Smith; Stephen S Rolfe; Teresa May; Robert L Trowbridge; Timothy L Hayes; Gene A Grindlinger; David B Seder
Journal:  Neurocrit Care       Date:  2017-12       Impact factor: 3.210

3.  Use and effectiveness of prothrombin complex concentrate in an emergency department: a review of 15 cases.

Authors:  Kei Suzuki; Yoshiaki Iwashita; Tomoyuki Enokiya; Kazuto Yokoyama; Masaki Fujioka; Naoyuki Katayama; Hiroshi Imai
Journal:  Acute Med Surg       Date:  2015-08-12

4.  Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding.

Authors:  D Imberti; A Magnacavallo; F Dentali; E Condoleo; M Gallerani; R Benedetti; W Ageno
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

5.  Fixed dose 4-factor prothrombin complex concentrate for the emergent reversal of warfarin: a retrospective analysis.

Authors:  Greta Astrup; Preeyaporn Sarangarm; Allison Burnett
Journal:  J Thromb Thrombolysis       Date:  2018-02       Impact factor: 2.300

6.  Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase 3b study.

Authors:  Shigeki Kushimoto; Toshio Fukuoka; Akio Kimura; Kazunori Toyoda; Andres Brainsky; Amy Harman; Thomas Chung; Masahiro Yasaka
Journal:  Int J Hematol       Date:  2017-08-16       Impact factor: 2.490

Review 7.  Fixed-dose 4-factor prothrombin complex concentrate: we don't know where we're going if we don't know how to get there.

Authors:  Scott T Hall; Kyle C Molina
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

8.  Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal.

Authors:  Wesley Zemrak; Francis Manuel; Kathryn E Smith; Stephen Rolfe; Timothy Hayes; Robert L Trowbridge; Brian Carlone; David Seder
Journal:  J Thromb Thrombolysis       Date:  2019-02       Impact factor: 2.300

Review 9.  Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature.

Authors:  Eric M Bershad; Jose I Suarez
Journal:  Neurocrit Care       Date:  2010-06       Impact factor: 3.210

10.  Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy.

Authors:  Cezary Wójcik; Michelle L Schymik; Eric G Cure
Journal:  Int J Emerg Med       Date:  2009-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.